Skip to content
Screener

Haemonetics HAE Q4 2026 Annual earnings

Reported May 7, 2026 · Before market open

Revenue$346.4MBeat by $9.5M
EPS$1.29Beat by $0.01
Revenue estimate$336.8M
EPS estimate$1.28

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$345.0M
EPS estimate$1.30

Financials

Q4 2026

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation & ratios

Valuation

as of 03/28/26
See full
Market cap$2.62B-18.0%
Enterprise value$3.65B-12.5%
P/S2×-0.4×

Profitability

See full
Gross margin59%+4.0pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Segments

By product

See full
Plasma$130.3M+2.8%

FAQ

When did Haemonetics report Q4 2026 earnings?
Haemonetics (HAE) reported Q4 2026 earnings on May 7, 2026 before market open.
What were Haemonetics's Q4 2026 revenue and EPS?
Haemonetics reported revenue of $346.4M and eps of $1.29 for Q4 2026.
Did Haemonetics beat estimates in Q4 2026?
Revenue beat the consensus estimate of $336.8M by $9.5M. EPS beat the consensus estimate of $1.28 by $0.01.
How did Haemonetics's Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.8% from $330.6M a year earlier and eps grew 4.0% from $1.24.
Where can I find Haemonetics's Q4 2026 SEC filings?
You can read the 8-K earnings release (0000313143-26-000031) and the 10-K periodic report (0000313143-26-000050) directly on SEC EDGAR. The filing index links above go to sec.gov.